1,720,974 research outputs found
Protocollo regionale diagnostico-terapeutico per la porpora trombocitopenica acuta in età pediatrica: risultati preliminari
No full textImaging of empyema (EMP) in children: How bedside ultrasonography (US) impact on clinical practice?
No full textImaging plays a central role in the diagnosis and management of childhood EMP. Although recent literature recommend the use of US as the central imaging investigation, its use is not as widespread as traditional radiology
Mandatory Pain Assessment in a Pediatric Emergency Department: Failure or Success? A Retrospective Study.
No full textDecision making at diagnosis in chronic myeloid leukemia
No full textThe diagnostic workup of Philadelphia positive (Ph+) chronic myeloid leukemia requires
physical examination, blood counts and differential, marrow aspirate for cytology and
cytogenetics, and the detection of BCR-ABL transcripts in marrow or blood. For patients
in early chronic phase, first line treatment is Imatinib (IM) 400 mg daily. Response is
monitored hematologically, cytogenetically (at least every 6 months) and molecularly by
RQ-PCR (every 3 months). The response is optimal when a complete hematologic
response is achieved in 3 months, a partial cytogenetic response in 6 months, a complete
cytogenetic response in 12 months, a major molecular response in 18 months, and
when the responses are stable over time. In case of suboptimal response or failure, a
patient may still have a survival benefit by continuing IM treatment at 400 mg daily, but
could or should be considered for IM dose increase to 600 and 800 mg, for second generation
tyrosine kinase inhibitors (Nilotinib and Dasatinib), and for allogeneic stem cell transplantation
Rituximab and factors predictive of response in chronic thrombocytopenic purpura in children
No full text
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables
No full textChronic myeloid leukemia (CML) is a myeloproliferative disorder characterized in 90-95% of cases by the reciprocal t(9;22)(q34;q11) chromosomal translocation, that generates a BCR-ABL fusion gene on the derivative chromosome 22 [der(22)] or Philadelphia (Ph) chromosome. The BCR-ABL gene encodes a constitutively active tyrosine kinase, which leads to the activation of multiple signaling pathways involved in cell-cycle, adhesion and apoptosis. The aim of the chapter book was to bescribe risk statification models and prognostic factors, including baseline and response-related prognostic variables, with relevant impact on the outcome of CML patients
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
